Suppr超能文献

血小板衍生生长因子受体(PDGFRs)的表达及其与卵巢癌患者总生存期的相关性。

The expression of Platelet-derived Growth factor receptors (PDGFRs) and their correlation with overall survival of patients with ovarian cancer.

作者信息

Szubert Sebastian, Moszynski Rafal, Szpurek Dariusz, Romaniuk Bartlomiej, Sajdak Stefan, Nowicki Michal, Michalak Slawomir

机构信息

Clinical Department of Gynaecological Oncology, The Franciszek Lukaszczyk Oncological Center, Bydgoszcz, Poland.

Division of Gynecological Surgery, Poznan University of Medical Sciences, Poznan, Poland.

出版信息

Ginekol Pol. 2019;90(5):242-249. doi: 10.5603/GP.a2019.0045. Epub 2019 Apr 12.

Abstract

OBJECTIVES

The main aim of the study was to investigate the expression of Platelet-Derived Growth Factor Receptors alpha (PDGFR-alpha) and beta (PDGFR-beta) in malignant and benign ovarian tumors. We performed an analysis of the correlation of PDGFRs expression and stage of the disease, tumor grade and histopathological type of epithelial ovarian cancer (EOC). Additionally, we evaluated patient prognosis according to PDGFR expression.

MATERIAL AND METHODS

Our study group was composed of 52 samples of EOCs, 35 samples of benign ovarian tumors (BOTs), and 21 samples of unchanged ovaries (UOs). The samples were collected from patients who had been operated on in the Division of Gynecological Surgery of the Poznan University of Medical Sciences.

RESULTS

PDGFR-alpha was found to be expressed more frequently in cancer cells of EOCs, when compared with tumor cells of BOTs and epithelium of UOs. On the other hand, PDGFR-alpha receptors were present less frequently in the stroma of EOCs, when compared with the stroma of BOTs and UOs. Comparing the studied groups, there were no statistically significant differences in the expression of PDGFR-beta. The expression of both PDGFRs was not related to the FIGO stage, grade or histopathological type of EOCs. The expression of the PDGFR-beta receptor in cancer cells was associated with an improved overall survival among patients with EOCs. Patient prognosis was not affected by either PDGFR-alpha expres- sion or by PDGFR-beta tumor stroma expression.

CONCLUSIONS

The expression of PDGFR-alpha is significantly different when comparing EOCs, BOTs and UOs. However, the prognosis of EOC only seems to be affected by PDGFR-beta expression in cancer cells.

摘要

目的

本研究的主要目的是调查血小板衍生生长因子受体α(PDGFR-α)和β(PDGFR-β)在恶性和良性卵巢肿瘤中的表达情况。我们对PDGFRs表达与疾病分期、肿瘤分级以及上皮性卵巢癌(EOC)的组织病理学类型之间的相关性进行了分析。此外,我们根据PDGFR表达评估了患者的预后。

材料与方法

我们的研究组由52例EOC样本、35例良性卵巢肿瘤(BOT)样本和21例正常卵巢(UO)样本组成。这些样本取自在波兹南医科大学妇科手术科室接受手术的患者。

结果

与BOT的肿瘤细胞和UO的上皮相比,发现PDGFR-α在EOC的癌细胞中表达更频繁。另一方面,与BOT和UO的基质相比,PDGFR-α受体在EOC的基质中出现的频率较低。比较各研究组,PDGFR-β的表达没有统计学上的显著差异。两种PDGFR的表达均与EOC的国际妇产科联盟(FIGO)分期、分级或组织病理学类型无关。PDGFR-β受体在癌细胞中的表达与EOC患者总体生存率的提高相关。患者的预后不受PDGFR-α表达或PDGFR-β肿瘤基质表达的影响。

结论

比较EOC、BOT和UO时,PDGFR-α的表达存在显著差异。然而,EOC的预后似乎仅受癌细胞中PDGFR-β表达的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验